Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. [electronic resource]
Producer: 20191031Description: 143-153 p. digitalISSN:- 2326-5205
- Adult
- Aged
- Alanine Transaminase -- blood
- Aspartate Aminotransferases -- blood
- Colchicine -- therapeutic use
- Cough -- chemically induced
- Creatinine -- blood
- Delayed-Action Preparations
- Diarrhea -- chemically induced
- Double-Blind Method
- Drug Therapy, Combination
- Febuxostat -- administration & dosage
- Female
- Glomerular Filtration Rate
- Gout -- blood
- Gout Suppressants -- administration & dosage
- Headache -- chemically induced
- Humans
- Hypertension -- chemically induced
- Male
- Middle Aged
- Naproxen -- therapeutic use
- Nasopharyngitis -- chemically induced
- Renal Insufficiency, Chronic -- complications
- Respiratory Tract Infections -- chemically induced
- Severity of Illness Index
- Treatment Outcome
- Uric Acid -- blood
- gamma-Glutamyltransferase -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.